Previously researched by Oxford and AstraZeneca, a “90% effective” CoViD vaccine was only applied at a reduced dose in people under age 55.
What was hoped to be ready by year’s end will now need further research.
More trials will compare the reduced dose to a standard two-pair dosing of the vaccination.
‘Mr. Pangalos said the company [AstraZeneca] is planning a global trial to compare the two dosing regimens. The number of participants it will enroll hasn’t yet been determined, but it will be in the thousands.
“The only way they’re going to find out is by specifically and deliberately testing this serendipitous observation,” Professor Moore said. “The onus is on them to prove the speculation.” ‘